Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection

Imagem de Miniatura
Arquivos
art_LISBOA-NETO_Resistance_mutations_are_rare_among_protease_inhibitor_treatmentnaive_2015.PDF (625.2 KB)
Citações na Scopus
16
Tipo de produção
article
Data de publicação
2015
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
INT MEDICAL PRESS LTD
Autores
ALVARADO-MORA, Monica V.
SILVA, Mariliza H. da
LEITE, Andrea G. B.
PICCOLI, Leonora Z.
RODRIGUES, Flaviane K.
Citação
ANTIVIRAL THERAPY, v.20, n.3, p.281-287, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: HCV has a high replication rate and a lack of proofreading activity, leading to a greatly diverse viral population. This diversity may lead to emergence of resistant strains in direct-acting antiviral therapy. The frequency of naturally occurring HCV protease inhibitor (PI) mutations has been addressed in many countries, but there are few data on the prevalence of these mutations in Brazilian patients. Methods: We evaluated the sequence of HCV NS3 protease gene in 247 patients (135 HCV-monoinfected and 112 HIV-HCV-coinfected patients). HCV RNA was extracted from plasma and a fragment of 765 base pairs from the NS3 region was amplified and sequenced with Sanger-based technology. Results: HIV-HCV-coinfected patients were more likely to be older than 40 years and have an HCV subtype-1a infection. Overall, 21.9% of patients had at least one amino acid substitution in the NS3 region; 14 patients (5.7%) harboured at least one resistance mutation (T54S, V55A, Q80R) and the Q80K mutation was not found in our case series. There was no difference between monoinfected and coinfected patients regarding the frequency of natural polymorphisms and resistance mutations. Conclusions: Baseline HCV NS3 amino acid substitutions identified herein are considered mostly natural polymorphisms with no clinical impact on PI-based therapy. The identified resistance mutations may be associated with low-level resistance to PIs in vitro. Q80K substitution seems to be a rare event in Brazil. HIV coinfection was not associated with a greater frequency of such substitutions in the studied sample.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/11659
Referências
  1. Aguilera Guirao Antonio, 2006, Enferm Infecc Microbiol Clin, V24, P264, DOI 10.1016/S0213-005X(06)73773-9
  2. Barnard RJO, 2013, VIROLOGY, V444, P329, DOI 10.1016/j.virol.2013.06.029
  3. Bartels DJ, 2013, J VIROL, V87, P1544, DOI 10.1128/JVI.02294-12
  4. Campiotto S, 2005, BRAZ J MED BIOL RES, V38, P41, DOI 10.1590/S0100-879X2005000100007
  5. Campiotto S, 2002, 12 INT C VIR PAR 27
  6. Chevaliez S, 2013, J CLIN MICROBIOL, V51, P1078, DOI 10.1128/JCM.02004-12
  7. Gaudieri S, 2009, HEPATOLOGY, V49, P1069, DOI 10.1002/hep.22773
  8. Halfon P, 2008, AIDS, V22, P1694, DOI 10.1097/QAD.0b013e32830a989b
  9. HCV Phenotype Working Group HCV Drug Development Advisory Group, 2012, ANN FORUM COLLAB HIV, V14, P1
  10. Hoffmann L, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-57
  11. Kim AY, 2005, BLOOD, V105, P1170
  12. Kuntzen T, 2008, HEPATOLOGY, V48, P1769, DOI 10.1002/hep.22549
  13. Lenz O, 2010, ANTIMICROB AGENTS CH, V54, P1878, DOI 10.1128/AAC.01452-09
  14. Lin L, 2006, EUR J GASTROEN HEPAT, V18, P1311, DOI 10.1097/01.meg.0000243881.09820.09
  15. Maasoumy B, 2012, BEST PRACT RES CL GA, V26, P401, DOI 10.1016/j.bpg.2012.09.009
  16. Mendes-Correa MC, 2008, INT J STD AIDS, V19, P595, DOI 10.1258/ijsa.2007.007183
  17. Morsica G, 2009, JAIDS-J ACQ IMM DEF, V51, P106, DOI 10.1097/QAI.0b013e3181a02fda
  18. Nakano T, 2004, J INFECT DIS, V190, P1098, DOI 10.1086/422606
  19. Nishiya AS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086413
  20. Oliveira Silvano Barbosa de, 2014, Cad Saude Publica, V30, P433, DOI 10.1590/0102-311X00010413
  21. Olysio (simeprevir), OL SIM PRESCR INF 20
  22. Paolucci S, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-245
  23. Pereira LMMB, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-60
  24. Peres-da-Silva A, 2010, ARCH VIROL, V155, P807
  25. Rallon NI, 2012, JAIDS-J ACQ IMM DEF, V60, P117, DOI 10.1097/QAI.0b013e31824f5506
  26. Sandres-Saune K, 2003, J VIROL METHODS, V109, P187, DOI 10.1016/S0166-0934(03)00070-3
  27. Sarrazin C, 2012, J HEPATOL, V56, pS88, DOI 10.1016/S0168-8278(12)60010-5
  28. Soriano V, 2012, INFECT DIS CLIN N AM, V26, P931, DOI 10.1016/j.idc.2012.08.004
  29. Trevino A, 2011, ANTIVIR THER, V16, P413, DOI 10.3851/IMP1760
  30. Trimoulet P, 2011, HIV MED, V12, P506, DOI 10.1111/j.1468-1293.2011.00913.x
  31. Vermehren J, 2012, BEST PRACT RES CL GA, V26, P487, DOI 10.1016/j.bpg.2012.09.011
  32. Vicenti I, 2012, J ANTIMICROB CHEMOTH, V67, P984, DOI 10.1093/jac/dkr581
  33. Victrelis (boceprevir), VICTR BOC PRESCR INF
  34. Wegzyn CM, 2012, CURR OPIN PHARMACOL, V12, P556, DOI 10.1016/j.coph.2012.06.005
  35. Welsch C, 2012, GUT, V61, P36, DOI 10.1136/gutjnl-2012-302144
  36. Wyles DL, 2013, J INFECT DIS, V207, pS33, DOI 10.1093/infdis/jis761
  37. Zeminian LB, 2013, MEM I OSWALDO CRUZ, V108, P13, DOI 10.1590/S0074-02762013000100002

Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/06
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - ODS/03